Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Igm Biosciences Inc (IGMS)

Igm Biosciences Inc (IGMS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 962,154
  • Shares Outstanding, K 59,319
  • Annual Sales, $ 2,130 K
  • Annual Income, $ -246,420 K
  • EBIT $ -237 M
  • EBITDA $ -238 M
  • 60-Month Beta 0.20
  • Price/Sales 477.34
  • Price/Cash Flow N/A
  • Price/Book 8.30

Options Overview Details

View History
  • Implied Volatility 124.85% ( +3.75%)
  • Historical Volatility 108.04%
  • IV Percentile 64%
  • IV Rank 52.17%
  • IV High 194.08% on 08/28/24
  • IV Low 49.32% on 08/20/24
  • Put/Call Vol Ratio 0.50
  • Today's Volume 12
  • Volume Avg (30-Day) 57
  • Put/Call OI Ratio 1.14
  • Today's Open Interest 1,888
  • Open Int (30-Day) 1,910

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.82
  • Number of Estimates 7
  • High Estimate -0.77
  • Low Estimate -0.88
  • Prior Year -1.04
  • Growth Rate Est. (year over year) +21.15%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.01 +20.60%
on 10/10/24
20.35 -22.90%
on 10/22/24
+0.28 (+1.82%)
since 10/04/24
3-Month
7.48 +109.76%
on 08/05/24
22.50 -30.27%
on 09/17/24
+6.94 (+79.31%)
since 08/02/24
52-Week
4.12 +280.83%
on 11/10/23
22.50 -30.27%
on 09/17/24
+10.75 (+217.61%)
since 11/03/23

Most Recent Stories

More News
IGM Biosciences to Present at Three Upcoming Investor Conferences

IGMS : 15.69 (-3.27%)
Stock Index Futures Mixed Ahead of U.S. JOLTs Report and Fed Speak, Nike Earnings on Tap

December S&P 500 E-Mini futures (ESZ24) are down -0.13%, and December Nasdaq 100 E-Mini futures (NQZ24) are up +0.06% this morning as investors awaited the latest reading on U.S. job openings, comments...

CVS : 54.65 (-2.08%)
AAPL : 222.01 (-0.40%)
MKC : 78.18 (-0.72%)
IGMS : 15.69 (-3.27%)
F : 10.36 (+1.37%)
NQZ24 : 20,113.25 (+0.14%)
MU : 101.73 (+2.01%)
HPQ : 35.99 (-0.80%)
NKE : 77.19 (-1.11%)
1COV.D.DX : 58.060 (+0.14%)
PAYX : 139.68 (+0.42%)
UPS : 133.00 (-0.78%)
Change in Medivir's Board of Directors

/PRNewswire/ -- Medivir AB (Nasdaq: MVIR) and (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

IGMS : 15.69 (-3.27%)
Fostrox + Lenvima continues to show promising tumor control in HCC, all patients have now dosed at least two treatment cycles

/PRNewswire/ -- Medivir AB (Nasdaq:MVIR) (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...

IGMS : 15.69 (-3.27%)
Medivir to present at the Pareto Securities Healthcare Conference

/PRNewswire/ -- Medivir AB (Nasdaq: MVIR) (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...

IGMS : 15.69 (-3.27%)
Medivir's Partner Tango Therapeutics received FDA clearance to start the TNG348 phase 1/2 clinical study

/PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

IGMS : 15.69 (-3.27%)
Medivir presents data on additive activity of fostrox in combination with Lenvima or sorafenib in non-clinical tumor models at ILCA

/PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancers with high unmet medical...

IGMS : 15.69 (-3.27%)
Medivir reports promising interim data, including a first complete response in phase 1b/2a HCC study with fostrox in combination with Lenvima

/PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

IGMS : 15.69 (-3.27%)
Medivir Hosts Expert Perspectives Webcast on the Evolving Treatment Landscape and the Unique Treatment Challenges in HCC

/PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

IGMS : 15.69 (-3.27%)
Medivir to present at the Erik Penser Bank Company Event

/PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

IGMS : 15.69 (-3.27%)

Business Summary

IGM Biosciences Inc. is a biotechnology company. It engages in the research and development of engineered Immunoglobulin M antibodies for the treatment of cancer patients. The company's lead product candidate is IGM-2323, a bispecific T cell engaging IgM, which are in clinical stage. IGM Biosciences...

See More

Key Turning Points

3rd Resistance Point 17.73
2nd Resistance Point 17.00
1st Resistance Point 16.35
Last Price 15.69
1st Support Level 14.96
2nd Support Level 14.23
3rd Support Level 13.58

See More

52-Week High 22.50
Last Price 15.69
Fibonacci 61.8% 15.48
Fibonacci 50% 13.31
Fibonacci 38.2% 11.14
52-Week Low 4.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar